Evaluation of total adiponectin, adipocyte fatty acid binding protein and fibroblast growth factor 21 levels in individuals with metabolic syndrome

Physiological Research

Volumn 63, Issue 2, 2014, Pages 219-228

  Novotny D ^a   Vaverkova, H ^b   Karasek, D ^b   Lukes, J ^a   Slavik, L ^b   Malina, P ^c   Orsag, J ^b  

^a UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^b PALACKÝ UNIVERSITY   (Czech Republic)

^c Hospital Písek   (Czech Republic)

Author keywords

Adipocyte fatty acid binding protein; Adiponectin; Dyslipidemia; Fibroblast growth factor 21; Metabolic syndrome

Indexed keywords

ADIPONECTIN; ADIPOQ PROTEIN, HUMAN; BIOLOGICAL MARKER; FABP4 PROTEIN, HUMAN; FATTY ACID BINDING PROTEIN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 21;

ADULT; ASYMPTOMATIC DISEASE; BLOOD; DYSLIPIDEMIAS; EVALUATION STUDY; FEMALE; HUMAN; MALE; METABOLIC SYNDROME X; MIDDLE AGED;

ADIPONECTIN; ADULT; ASYMPTOMATIC DISEASES; BIOLOGICAL MARKERS; DYSLIPIDEMIAS; FATTY ACID-BINDING PROTEINS; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED;

EID: 84899981949     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. CHEN C, CHEUNG BM, TSO AW, WANG Y, LAW LS, ONG KL, WAT NM, XU A, LAM KS: High plasma level of fibroblast growth factor 21 is an independent predictor of type 2 diabetes: a 5.4-year population based prospective study in Chinese subjects. Diabetes Care 34: 2113-2115, 2011.
2. COSKUN T, BINA HA, SCHNEIDER MA, DUNBAR JD, HU CC, CHEN Y, MOLLER DE, KHARITONENKOV A: Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149: 6018-6027, 2008.
3. DIAZ-DELFIN J, HONDARES E, IGLESIAS R, GIRALT M, CAELLES C, VILLARROYA F: TNF-alpha represses beta-Klotho expression and impairs FGF21 action in adipose cells; involvement of JNK1 in the FGF21 pathway. Endocrinology 153: 4238-4245, 2012.
4. DOSTALOVA I, HALUZIKOVA D, HALUZIK M: Fibroblast Growth Factor 21: A novel metabolic regulator with potential therapeutic properties in obesity/type 2 diabetes mellitus. Physiol Res 58: 1-7, 2009.
5. ECKEL RH, GRUNDY SM, ZIMMENT PZ: The metabolic syndrome. Lancet 365: 1415-1428, 2005.
6. FISHER FM, CHUI PC, ANTONELLIS PJ, BINA HA, KHARITONENKOV A, FLIER JS, MARATOS-FLIER E: Obesity is a fibroblast growth factor (FGF 21)-resistant state. Diabetes 59: 2781-2789, 201
7. FRYSTYK L, BERNE C, BERGLUND L, JENSEVIK K, FLYVBJERG A, ZETHELIUS B: Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. J Clin Endocrinol Metab 92: 571-576, 2007.
8. FUNAHASHI T, NAKAMURA T, SHIMOMURA I, MAEDA K, KURIYAMA H, TAKAHASHI M, ARITA Y, KIHARA S, MATSUZAWA Y: Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. Intern Med 38: 202-206, 1999.
9. FURUNAHASHI M, HOTAMISLIGIL GS: Fatty acid-binding proteins: role in metabolic diseases and potential as a drug targets. Nat Rev Drug Discover 7: 489-503, 2008.
10. HALUZIK M, PARIZKOVÁ J, HALUZIK MM: Adiponectin and its role in the obesity-induced insulin resistance and related complications. Physiol Res 53: 123-129, 2004.
11. HALUZIK MM, ANDERLOVA K, DOLEZALOVA R, ADAMIKOVA A, HALUZIKOVA D, HOUSOVA J, SVACINA S, HALUZIK M: Serum adipocyte fatty acid binding protein levels in patients with type 2 diabetes mellitus and obesity: the influence of fenofibrate treatment. Physiol Res 58: 93-99, 2009.
12. HAN TS, WILLIAMS K, SATTAR N, HUNT KJ, LEAN ME, HAFFNER SM: Analysis of obesity and hyperinsulinemia in the development of metabolic syndrome: San Antonio Heart Study. Obes Res 10: 923-931, 2002.
13. HOO RC, YEUNG CY, LAM KS, XU A: Inflammatory biomarkers associated with obesity and insulin resistance: a focus on lipocalin-2 and adipocyte fatty acid-binding protein. Expert Rev Endocrinol Metab 3: 29-41, 2008.
14. HORAKOVA D, PASTUCHA D, STEJSKAL D, KOLLAROVA H, AZEEM K, JANOUT V: Adipocyte fatty acid binding protein and C-reactive protein levels as indicators of insulin resistance development. Biomed Pap Med Fac Univ Palacky Olomouc Czech Rep 155: 355-359, 2011.
15. HUATING L, JING Z, WEIPING J: Fibroblast growth factor 21: a novel metabolic regulator from pharmacology to physiology. Front Med 7: 25-30, 2013.
16. IGLESIAS P, SELGAS R, ROMERO S, DÍEZ J: Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21. Eur J Endocrinol 167: 301-309, 2012.
17. KARASEK D, VAVERKOVA H, FRYSAK Z, ORSAG J, NOVOTNY D, HALENKA M, SLAVIK L: Realtionship between serum adipocyte acid-binding protein and endothelial/hemostatic markers in dyslipidemic subjects. Neuroendocrinol Lett 33: 26-31, 2012.
18. KHARITONENKOV A, WROBLEWSKI V, KOESTER A, CHEN YF, CLUTINGER CK, TIGNO XT, HANSEN BC, SHANAFELT AB, ETGEN GJ: The metabolic state of diabetic monkeys is regulated by fibroblast growth factor 21. Endocrinology 148: 774-781, 2007.
19. KHARITONENKOV A, DUBNAR JD, BINA HA, BRIGHT S, MOYERS JS, ZHANG C, DING L, MICANOVIC R, MEHRBOD SF, KNIERMAN MD, HALE JE, COSKUN T, SHANAFELT AB: FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho. J Cell Physiol 215: 1-7, 2008.
20. KRALISCH S, FASSHAUER M: Fibroblast growth factor 21: effects on carbohydrate and lipid metabolism in health and disease. Curr Opin Clin Nutr Metab Care 14: 354-359, 2011.
21. KRALISCH S, FASSHAUER M: Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease? Diabetologia 56: 10-21, 2013.
22. LAMOUNIER-ZEPTER V, LOOK C, ALVAREZ J, CHRIST T, RAVENS U, SCHNUCK WH, EHRHARTBORNSTEIN M, BORNSTEIN SR, MORANO I: Adipocyte fatty acid-binding protein suppresses cardiomyocyte contraction: a new link between obesity and heart disease. Circ Res 105: 326-334, 2009.
23. LIBBY P, OKAMOTO Y, ROCHA VZ, FOLCO E: Inflammation in atherosclerosis: transition from theory to practice. Circ J 74: 213-220, 2011.
24. LIN Z, WU Z, YIN X, LIU Y, YAN X, LIN S, XIAO J, WANG X, FENG W, LI X: Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PloS One 5: e15534, 2010.
25. LINDSAY RS, RESNICK HE, ZHU J, TUN ML, HOWARD BV, ZHANG Y, YEH J, BEST LG: Adiponectin and coronary heart disease: the Strong Heart Study. Arterioscler Thromb Vasc Biol 25: e15-e16, 2005.
26. MIYOSHI T, ONOUE G, HIROHATA A, HIROHATA S, USUI S, HINA K, KAWAMURA H, DOI M, KUSANO KF, KUSACHI S, NINOMIYA Y: Serum adipocyte fatty acid-binding protein is independently associated with coronary atherosclerotic burden measured by intravascular ultrasound. Atherosclerosis 211: 164-169, 2010.
27. PARK SE, RHEE EJ, LEE WY, KIM WJ, YOO SH, BAE JC, CHOI ES, PARK CY, OH KW, PARK SW, KIM SW: The role of serum adipocyte fatty acid-binding protein on the development of metabolic syndrome is independent of pro-inflammatory cytokines. Nutr Metab Cardiovascular Dis 22: 525-532, 2012.
28. PISCHON T, GIRMAN CJ, HOTAMISLIGIL CS, RIFAI N, HU FB, RIMM EB: Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291: 1730-1737, 2004.
29. REINEHR T, WOELFLE J, WUNSCH R, ROTH CL: Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis. J Clin Endocrinol Metab 97: 2143-2150, 2012.
30. RHEE EJ, LEE WY, PARK CY, OH KW, KIM BJ, SUNG KC, KIM BS: The association of serum adipocyte fatty acid-binding protein with coronary artery disease in Korean adults. Eur J Endocrinol 160: 165-172, 2009.
31. RYO M, NAKAMURA T, KIHARA S, KUMADA M, SHIBAZAKI S, TAKAHASHI M, NAGAI M, MATSUZAWA Y, FUNAHASHI T: Adiponectin as a biomarker of the metabolic syndrome. Circ J 68: 975-981, 2004.
32. SAELY CH H, RISCH L, HOEFLE G, REIN P, MUENDLEIN A, MARTE T, ACZEL S, LANGER P, DREXEL H: Low serum adiponectin is independently associated with both the metabolic syndrome and angiographically determined coronary atherosclerosis. Clin Chim Acta 383: 97-102, 2007.
33. SHIMADA K, MIYAZAKI T, HIROYUKI D: Adiponectin and atherosclerotic disease. Clin Chim Acta 344: 1-12, 2004.
34. TAO L, GAO E, JIAO X, YUAN Y, LI S, CHRISTOPHER TA, LOPEZ BL, KOCH W, CHAN L, GOLDSTEIN BJ, MA XL: Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrosative stress. Circulation 115: 1408-1416, 2007.
35. VAVERKOVA H, KARASEK D, NOVOTNY D, KOVAROVA D, HALENKA M, SLAVIK L, FROLICH J: Positive association of adiponectin with soluble thrombomodulin, von Willebrand factor and soluble VCAM-1 in dyslipidemic subjects. Clin Biochem 46: 766-771, 2013.
36. VON EYNATTEN M, HAMANN A, TWARDELLA D, NAWROTH PP, BRENNER H, ROTHENBACHER D: Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary heart disease. Clin Chem 52: 853-859, 2006.
37. WOO YC, XU A, WANG Y, LAM KS: Fibroblast growth factor 21 as an emerging metabolic regulator. Clin Endocrinol 78: 489-496, 2013.
38. XU A, VANHOUTTE PM: Adiponectin and adipocyte fatty acid binding protein in the pathogenesis of cardiovascular disease. Am J Physiol Heart Circ Physiol 302: H1231-H1243, 2012.
39. XU A, WANG Y, XU JY, STEJSKAL D, TAM S, ZHANG J, WAT NM, WONG WK, LAM KS: Adipocyte fatty acid binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 52: 405-413, 2006.
40. ZHANG X, YEUNG DC, KARPISEK M, STEJSKAL D, ZHOU ZG, LIU F, WONG RL, CHOW WS, TSO AW, LAM KS, XU A: Serum FGF21 levels are increased in obesity and are independently associated with metabolic syndrome in humans. Diabetes 57: 1246-1253, 2008.
41. ZHOU M, BAO Y, LU J, ZHOU J, JIA W: Serum A-FABP is increased and closely associated with elevated NTproBNP levels in type 2 diabetic patients treated with rosiglitazone. PLoS One 6: e27032, 2011.